GSK Acquires Rapt Therapeutics for $2.2 Billion to Secure Food Allergy Drug Ozureprubart

GSK agreed to acquire Rapt Therapeutics for $58 per share in cash, valuing the clinical-stage biotech at $2.2 billion in equity and requiring a net cash commitment of $1.9 billion after accounting for Rapt’s cash position.[1][5]

Most “AI for Diligence” tools are lying to you. The truth is, they are just ChatGPT wrappers. Experience what real AI for Diligence looks like, built like Claude Code, but for M&A/ PE Diligence:

💼 When Claude Code Marries Due Diligence!

The deal, GSK’s first under new CEO Luke Miels, grants the British drugmaker global rights—excluding mainland China, Macau, Taiwan, and Hong Kong—to ozureprubart, Rapt’s Phase 2b anti-IgE monoclonal antibody for prophylactic food allergy protection.[1][2][5] Expected to close in Q1 2026 via a tender offer and merger, the transaction bolsters GSK’s respiratory and immunology pipeline amid pressures on its HIV and vaccines segments.[1][5]

Deal Rationale and Strategic Fit

Ozureprubart targets immunoglobulin E (IgE), the only approved systemic therapy protecting against allergic and inflammatory responses in food allergy patients.[3] Unlike Roche’s Xolair, which requires bi-weekly injections, ozureprubart offers 12-week dosing, positioning it as a potential best-in-class option.[1][7] Phase 2b data are due in 2027, with GSK planning late-stage trials for adults and children.[1]

GSK Chief Scientific Officer Tony Wood described ozureprubart as a “promising new, potential best-in-class treatment.” Leerink Partners, downgrading Rapt to Market Perform at $58, noted GSK’s lack of clinical trials in food allergy and urticaria—ozureprubart’s lead indications—indicating minimal overlap and low regulatory risk.[1]

Rapt President and CEO Brian Wong highlighted GSK’s global development and commercialization strengths. The acquisition complements GSK’s immunology focus, filling gaps in anti-IgE assets.[1]

Financial Terms and Market Reaction

[1]

GSK assumes future milestone and royalty obligations to Rapt partner Shanghai Jeyou Pharmaceutical.[1] Rapt shares traded near their 52-week high post-announcement.[1]

Broader M&A Trends in Pharma Immunology

This deal signals renewed Big Pharma interest in immunology assets amid **biopharma M&A trends 2026**, with GSK joining recent activity like Boston Scientific’s $14.5B Penumbra buy and Lilly’s $1.2B Ventyx acquisition targeting NLRP3 inflammasomes.[5] Food allergy treatments represent a high-unmet-need niche, competing directly with Xolair in a market projected to grow with rising allergy prevalence.[2][7]

Analysts view mature biopharma acquisitions of emerging biotechs as dominant, driven by pipeline gaps and valuation discipline in a post-2025 IPO slowdown.[2] GSK’s move aligns with **strategic pharma acquisitions in allergy treatments**, enhancing long-term revenue as HIV/vaccines face headwinds.[5]

Implications for Stakeholders

• GSK Investors: Pipeline diversification into underserved allergy space, with ozureprubart’s extended dosing as a differentiator.
• Rapt Shareholders: Immediate liquidity at a premium, though Leerink trimmed its target.[1]
• Patients: Potential for less frequent dosing in food allergy prophylaxis if trials succeed.
• Industry: Heightened competition in anti-IgE therapies; watch for regulatory scrutiny in concentrated immunology M&A.[1][5]

GSK’s $2.2B bet underscores **private equity exit strategies in biotech** parallels, as Big Pharma absorbs late-stage assets to de-risk innovation.[1][2]